Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14910845 | 0.90 | LMNA (0.51) | MAPTALDH1A1CYP1A2CYP2C9HPGD | |
| SCHEMBL3356597 | 0.89 | ALDH1A1 (0.47) | MAPTALDH1A1CYP1A2CYP2C9HPGD | |
| SCHEMBL10076887 | 0.85 | ALDH1A1 (0.52) | MAPTALDH1A1CYP1A2CYP2C9HPGD | |
| SCHEMBL17585425 | 0.79 | CCR5 (0.46) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL14928355 | 0.79 | BRAF (0.46) | MAPTSMN1; SMN2MAPK1KDM4E | |
| SCHEMBL16168982 | 0.78 | MAPT (0.39) | MAPTALDH1A1LMNAPOLBKMT2A | |
| SCHEMBL14928321 | 0.74 | CYP19A1 (0.38) | MAPTALDH1A1CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL14928338 | 0.74 | ALDH1A1 (0.39) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL14397720 | 0.74 | KMT2A (0.54) | MAPTALDH1A1CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL14928319 | 0.74 | MAPT (0.43) | MAPTALDH1A1CYP2C9SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | MAPT 4186/4885ALDH1A1 1638/4885CYP1A2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.